Navigation Links
Stem cell therapy reverses diabetes

Type 1 diabetes is caused by the body's own immune system attacking its pancreatic islet beta cells and requires daily injections of insulin to regulate the patient's blood glucose levels. A new method described in BioMed Central's open access journal BMC Medicine uses stem cells from cord blood to re-educate a diabetic's own T cells and consequently restart pancreatic function reducing the need for insulin.

Stem Cell Educator therapy slowly passes lymphocytes separated from a patient's blood over immobilized cord blood stem cells (CBSC) from healthy donors. After two to three hours in the device the re-educated lymphocytes are returned to the patient. The progress of the patients was checked at 4, 12, 24 and 40 weeks after therapy.

C-peptide is a protein fragment made as a by-product of insulin manufacture and can be used to determine how well beta cells are working. By 12 weeks after treatment all the patients who received the therapy had improved levels of C peptide. This continued to improve at 24 weeks and was maintained to the end of the study. This meant that the daily dose of insulin required to maintain their blood glucose levels could be reduced. In accordance with these results the glycated hemoglobin (HbA1C) indicator of long term glucose control also dropped for people receiving the treatment, but not the control group.

Dr Yong Zhao, from University of Illinois at Chicago, who led the multi-centre research, explained, "We also saw an improved autoimmune control in these patients. Stem Cell Educator therapy increased the percentage of regulatory T lymphocytes in the blood of people in the treatment group. Other markers of immune function, such as TGF-beta1 also improved. Our results suggest that it is this improvement in autoimmune control, mediated by the autoimmune regulator AIRE in the CBSC, which allows the pancreatic islet beta cells to recover."

Contact: Dr Hilary Glover
BioMed Central

Page: 1

Related biology technology :

1. Squamous Cell Cancer Responds to SPDT Therapy
2. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
4. Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
5. Gene Therapy - Technologies, Markets and Companies
9. NeoStem Acquires Amorcyte, a Clinical Stage Cardiovascular Disease Cell Therapy Company
Post Your Comments:
Breaking Biology Technology:
Breaking Biology News(10 mins):